PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Mercaptopurine - Inflammatory bowel disease
PAD Profile : Mercaptopurine - Inflammatory bowel disease Important
Keywords :
6MP, IBD, UC, Ulcerative Colitis, thiopurines, Crohn's Disease
Brand Names Include :
Puri-Nethol
Important Information :
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Adalimumab
- Azathioprine
- Infliximab
- Ciclosporin
- Golimumab
- Vedolizumab
- Allopurinol
- Balsalazide sodium
- Prednisolone
- Budesonide
- Ustekinumab
- Guidelines
- Tofacitinib
- Methotrexate
- Mesalazine
- Filgotinib
- Darvadstrocel
- Ozanimod
- Sulfasalazine
- Upadacitinib
- Mirikizumab
- Risankizumab
- Etrasimod
- Olsalazine sodium
Other Indications
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 December 2021
Guidelines (Local)
01 December 2021
Committee Recommendations
Date
Committee Name
Narrative
02 August 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a local adaptation of the National Shared Care document, in reference to the routine monitoring of CRP (rather than ESR) in primary care for inflammatory indications
05 October 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the National Shared Care Protocol for azathioprine and mercaptopurine for patients in adult services (non- transplant indications)
Associated BNF Codes
08. Malignant Disease and Immunosuppression
08.02.01. Antiproliferative immunosuppressants